EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds through analysis of U.S. longitudinal ...
Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced the ...
T3D-959, an oral dual delta/gamma peroxisome proliferator-activated nuclear receptor (PPAR) agonist, has shown promise in a phase 2 randomized, placebo-controlled study of adults with mild-to-moderate ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting I. This abstract does not include a full text component.
Annals of Nutrition & Metabolism, Vol. 75, No. 3 (2019), p. 197 (1 page) Liang J, Lan J, Li M, Wang F. Associations of Leptin Receptor and Peroxisome Proliferator-Activated Receptor Gamma ...
Correlative analyses between EGFR pathways and stroma-tumor profiles in head and neck cancer patients (HNSCC) on postoperative radiotherapy plus cisplatin (PORTc) plus or minus gefitinib ...
The European Medicines Agency (EMA) has swatted away Minoryx Therapeutics’ attempt to bring a rare disease drug candidate to market on the strength of a clinical trial that missed its primary endpoint ...
Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the U.S. Despite recent advances, the five-year survival rate for metastatic UC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback